Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients-Reference-Cited by-同舟云学术

Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients

Published:2016-09 Issue:14 Volume:17 Page:1519-1531
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Zhang Dao-Yu¹²,Yuan Xiao-Qing¹²,Yan Han¹²,Cao Shan¹²,Zhang Wei¹²,Li Xiao-Lin³,Zeng Hui³,Chen Xiao-Ping¹²⁴

Affiliation:

1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, PR China

2. Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, PR China

3. Department of Hematology, Xiang-Ya Hospital, Central South University, Changsha 410008, Hunan, PR China

4. Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang 421001, Hunan, PR China

Abstract

Aim: DCK is a rate-limiting enzyme in cytarabine activation. rs4643786 and rs67437265 (P122S) variants are reported to affect DCK activity. Patients & methods: A total of 282 newly diagnosed acute myeloid leukemia (AML) patients were treated with cytarabine combined chemotherapy and genotyped for rs4643786 and rs67437265. Prognosis data were obtained through regular follow-up. DCK mRNA expression was detected in pretreatment blood or bone marrow mononuclear cells. Results: rs4643786 showed strong linkage disequilibrium with rs67437265. rs4643786 CT heterozygotes showed significantly higher complete remission rate (p = 0.028), superior overall survival (p = 0.006) and relapse-free survival (p = 0.020) than wild-type TT homozygotes. rs4643786 polymorphism was an independent predictor for AML prognosis. Conclusion: DCK rs4643786 may serve as an independent predictor of drug response and AML outcome.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2016-0084

Reference46 articles.

1. Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia

2. Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?

3. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia

4. Correlation between FLT3–ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias

5. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy;Pharmacogenomics and Personalized Medicine;2023-03

2. Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?;European Journal of Drug Metabolism and Pharmacokinetics;2022-08-01

3. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives;Pharmaceutics;2022-03-03

4. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation;Journal of Clinical Oncology;2022-03-01

5. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients;European Journal of Pharmacology;2021-03